Clinical Trials Logo

Arthritis, Juvenile Rheumatoid clinical trials

View clinical trials related to Arthritis, Juvenile Rheumatoid.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06000566 Completed - Quality of Life Clinical Trials

Drug Compliance and Affecting Factors in Juvenile Idiopathic Arthritis

Start date: December 1, 2022
Phase:
Study type: Observational

The goal of this observational study is to learn about the drug compliance of patients with juvenile idiopathic arthritis and, to figure our factors that affect the compliance. The main questions it aims to answer are: - Medication use and compliance in children with chronic diseases is an important problem, but do patients with JIA really use their medications in harmony? - Does the level of adherence to medications affect the quality of life of patients with JIA? Participants will be asked to fill the demographic form which includes personal information and nutritional habbits, Morisky Drug Compliance Scale - 8 and the pediatric quality of life inventory forms, with attending researcher Yesfa Sebnem Ozbay, M.D. This study is not an interventional study.

NCT ID: NCT02067962 Completed - Clinical trials for Arthritis, Juvenile Rheumatoid

Identification of Genes Involved in Juvenile Idiopathic Arthritis by Wholel Exome Sequencing

GenesinJIA
Start date: March 5, 2014
Phase: N/A
Study type: Interventional

Juvenile idiopathic arthritis (JIA) is considered to be a multifactorial disease caused by a combination of environmental factors and predisposing genetic factors. Twins studies found a strong heritability (strong genetic factors) but genetic studies such association studies of large cohorts of patient (GWAS or Genome Wide Association Study) have elucidated less than 20 % of the genetic basis of JIA. The vision of the genetics of multifactorial diseases has recently changed revealing a large clinical and genetic heterogeneity of these diseases. Indeed, the advent of next-generation sequencing identified non-multifactorial genetic hereditary disease related to mutations in genes having strong effect on the onset of the disease without real impact of environmental factors among the so called "multifactorial diseases" (Parkinson's, diabetes, osteoarthritis, Alzheimer's, hypertension ...)The investigators propose to study 30 families with several forms of JIA by next-generation sequencing. Identifying the genetic basis of JIA in these families will help to better understand the physiopathology of this disease and may help to the identification of novel therapeutic targets for other patients with JIA.

NCT ID: NCT02001844 Completed - Clinical trials for Arthritis, Juvenile Rheumatoid

Foot Orthoses (FOs) on Pain, Quality of Life and the Gait With Children Diagnosed With JIA

Start date: May 2009
Phase: N/A
Study type: Interventional

Modern modular foot-orthoses systems allow an integration of the cost and efficiency benefits afforded by the use of pre-formed semi-rigid FOs components, while simultaneously allowing a high degree of individualisation of prescription. Such systems, while popular, still remain unproven. Recent studies in paediatric rheumatology have made a contribution in developing guidelines with regards to pharmacological intervention in arthritic children. In addition, specific drug therapy protocols have been published to effectively help general practitioners, physiotherapists and ophthalmologists to successfully treat children with JIA patients (BSPAR 2006; Hull 2001; NICE guidelines 2002). A Cochrane systematic review on treatment of pes planus, highlighted that children with JIA were excluded as a group from most of the studies (Ashford et al. 2005). At present little evidence exists for the podiatric management of children affected by this disabling pathology, especially for orthotic management. This research has provided evidence to support the use of readily available off-the-shelf FOs in treating JIA children.

NCT ID: NCT01412021 Completed - Clinical trials for Arthritis, Juvenile Rheumatoid

Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis

Start date: July 1, 2011
Phase:
Study type: Observational

This study of Humira will be conducted to clarify the following with regard to the treatment of juvenile idiopathic arthritis affecting multiple joints with this drug: - Unknown adverse drug reactions (especially important adverse drug reactions) - Incidence and conditions of occurrence of adverse reactions in the clinical setting - Factors that may affect the safety and effectiveness of Humira

NCT ID: NCT00807846 Completed - Clinical trials for Arthritis, Juvenile Rheumatoid

A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects

Start date: September 2009
Phase: Phase 4
Study type: Interventional

This Is A Multicenter, Active-Controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis

NCT ID: NCT00731965 Completed - Clinical trials for Arthritis, Juvenile Rheumatoid

Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis

VAART
Start date: May 2008
Phase: Phase 4
Study type: Interventional

Background: The safety of vaccination in patients with autoimmune diseases using immune suppressive therapy is often discussed. Previous studies in Juvenile Idiopathic Arthritis (JIA) patients showed no increase in disease activity after immunisation with dead vaccines. The safety of the live attenuated Measles, Mumps, Rubella (MMR) vaccination was assessed retrospectively in JIA patients and no increase in disease activity was found. However, this must be prospectively confirmed. In addition, it is unknown whether vaccination is effective, since the immune response to vaccination may be diminished due to immunosuppressive therapy for the underlying disease. Finally, the influence of MMR vaccination on the immune system of JIA patients has not been studied. Among others, regulatory T-cells (Tregs) should control the immune response and prevent destructive autoimmune responses after environmental triggers such as vaccination. Objective: The aim of the present study is to investigate the safety and efficacy of the MMR booster vaccination and its influence on immune regulatory mechanisms in children with Juvenile Idiopathic Arthritis. Method: JIA patients aged 4 to 8 years and treated by the pediatric rheumatology units from various University Medical Centers in the Netherlands, are asked to participate in a prospective study. In the Netherlands, measles-mumps-rubella (MMR) vaccination is included in the National Vaccination Program and is normally administered at age 9. Included patients will be randomised for early vaccination (age group 4 to 8yr at entry of the study) or at age 9 as is routinely done according to the National Vaccination Program. Prior to and after vaccination the investigators will assess disease activity and collect blood. Outcome: During a 12 month follow-up period the investigators will register disease activity and side-effects at different moments in time to determine safety of vaccination. The efficacy of the vaccine will be studied according to antibody levels and function against measles, mumps and rubella in the blood. Tregs will be isolated and their functionality will be determined using the blood cells collected during follow-up. This enables us to study the role influence of vaccination on regulatory mechanisms in our immune system.

NCT ID: NCT00652925 Completed - Clinical trials for Arthritis, Juvenile Rheumatoid

A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA

Start date: October 2002
Phase: Phase 3
Study type: Interventional

To study Celebrex versus naproxen to see if it decreases symptoms of juvenile arthritis such as pain and swelling.

NCT ID: NCT00426218 Completed - Clinical trials for Arthritis, Juvenile Rheumatoid

Safety, Efficacy and Pharmacokinetics of Subcutaneous ACZ885 in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)

Start date: December 2006
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a multi-center, open label, repeated dose, range finding study to evaluate the safety, tolerability, immunogenicity, pharmacokinetics and efficacy of ACZ885, a fully human anti-interleukin-1B (anti-IL-1B) monoclonal antibody, given subcutaneously in pediatric subjects with active SJIA.

NCT ID: NCT00279747 Completed - Clinical trials for Arthritis, Juvenile Rheumatoid

A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA)

Start date: September 2000
Phase: Phase 3
Study type: Interventional

A one year double-blind trial to investigate the efficacy and safety of meloxicam oral suspension 0.25 mg/kg and 0.125 mg/kg administered once daily in comparison to naproxen oral suspension 5 mg/kg administered twice daily in children with Juvenile Rheumatoid Arthritis.

NCT ID: NCT00034853 Completed - Clinical trials for Arthritis, Juvenile Rheumatoid

Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)

Start date: December 2000
Phase: Phase 3
Study type: Interventional

To obtain safety, efficacy, pharmacokinetic and dosing information for meloxicam oral suspension in children with Juvenile Rheumatoid Arthritis (JRA)